Clinical Trial Update: A Study Of PF-06647263 In Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of PF-06647263 in advanced solid tumors; terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms
• Triple-negative Breast Cancer

Drugs mentioned

• PF-06647263

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Triple-Negative Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-04-29